1. Australia Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Genetic Signatures Ltd.

Genetic Signatures Ltd.

AASX:GSS
0.09
AUD
+0.00
(+2.38%)
-0.06EPS
15.22MMarket Cap
Feb 16Next Earn
Genetic Signatures Ltd.
ASX:GSS
(Australian Securities Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
- -
0.02
0.03
0.02
0.03
0.05
0.09
0.19
0.24
0.15
0.06
0.07
0.06
Revenue per Share
- -
-0.05
-0.04
-0.03
-0.03
-0.03
-0.02
0.01
0.02
-0.1
-0.11
-0.09
-0.06
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.23
0.09
0.07
0.15
0.13
0.1
0.31
0.34
0.37
0.29
0.28
0.22
0.16
Book Value per Share
0.23
0.09
0.07
0.15
0.13
0.1
0.31
0.33
0.36
0.25
0.25
0.22
0.16
Tangible Book Value per Share
70
52
72
98
106
106
130
146
147
147
165
227
227
Basic Weighted Avg Shares
- -
1
2
2
3
5
11
28
35
21
10
16
14
Sales/Revenue/Turnover
- -
-297.78
-249.75
-242.7
-198.47
-118.33
-44.06
4.8
8.09
-69.04
-228.68
-116.23
-122.76
Operating Margin (%)
- -
- -
- -
- -
1
- -
1
1
2
2
2
2
2
Depreciation Expense
- -
-3
-3
-3
-3
-3
-2
2
3
-14
-18
-20
-14
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-254.88
-165.84
-156.47
-114.57
-71.76
-18.52
6.21
8.65
-65.79
-182.9
-126.44
-96.91
Profit Margin (%)
16
6
5
16
12
9
43
43
46
30
47
44
33
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
LT Debt
16
7
5
16
13
11
46
49
55
43
61
50
36
Total Equity
- -
- -
- -
- -
- -
- -
- -
2.82
5.48
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
3.72
5.89
- -
- -
- -
- -
Return on Capital (%)
- -
-22.89
-51.52
-30.87
-22.16
-29.14
-7.38
3.69
5.88
-28.76
-34.34
-36.16
-32.64
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53%
-2.99%
-28.69%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-68.47%
-95%
-30.33%
Sales/Revenue/Turnover
38.99%
-3.01%
-9.1%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10
2025
- -
- -
16
2026
- -
- -
14

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.11
2025
- -
- -
-0.09
2026
- -
- -
-0.06

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Genetic Signatures Limited (ASX:GSS) develops and commercializes molecular diagnostics products utilizing its proprietary 3base platform technology for multiplex real-time PCR assays that detect infectious pathogens with high specificity and rapid throughput; the company manufactures and sells a suite of EasyScreen branded detection kits including EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection Kit, EasyScreen Viral Meningitis Detection Kit, EasyScreen Gastrointestinal Parasite Detection Kit, respiratory pathogen kits, SARS-CoV-2 kits, atypical respiratory kits, enteric bacteria kits, enteric viral kits, enteric protozoan kits, and others for routine screening in hospitals, pathology labs, and research settings. Founded in 2001 and headquartered in Newtown, Sydney, Australia, the company operates globally across the Asia Pacific, Europe, Middle East and Africa (EMEA), and Americas regions, with facilities including a production site in Maroubra, Australia; BioHub Birmingham in the United Kingdom; and Los Angeles BioLabs in the United States to support R&D, manufacturing, training, and regional expansion. In recent developments, Genetic Signatures reported 136% revenue growth to AU$8.5 million in the first half of FY25 driven by strong respiratory sales in Australia, secured its first U.S. commercial contract in February 2025, shifted strategic focus from internal instrument development to customizing commercial automated solutions for cost reduction and faster market entry, expanded promotion of its FDA 510(k)-cleared EasyScreen Gastrointestinal Parasite Detection Kit, announced a strategic partnership with Tecan and Repado in July 2025, and released its 2025 Annual Report detailing full-year financial results and performance highlights.